As filed with the Securities and Exchange Commission on March 14, 2024
Registration No. 333-_____
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
CULLINAN ONCOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware |
81-3879991 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
One Main Street Suite 1350 Cambridge, MA |
02142 |
(Address of principal executive offices) |
(Zip Code) |
Cullinan Oncology, Inc. 2021 Stock Option and Incentive Plan
Cullinan Oncology, Inc. 2021 Employee Stock Purchase Plan
(Full Title of the Plan)
Nadim Ahmed
President and Chief Executive Officer
Cullinan Oncology, Inc.
One Main Street
Suite 1350
Cambridge, MA 02142
(Name and Address of Agent For Service)
(617) 410-4650
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|
||
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Statement of Incorporation by Reference
This Registration Statement on Form S-8, relating to the 2021 Stock Option and Incentive Plan (the “2021 Stock Plan”) of Cullinan Oncology, Inc. (formerly Cullinan Management, Inc.) (the “Registrant”) and the 2021 Employee Stock Purchase Plan of the Registrant (the “ESPP”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8, File No. 333-251943, filed with the Securities and Exchange Commission (the “SEC”) on January 7, 2021 by the Registrant, relating to the 2021 Stock Plan and the ESPP, (ii) the Registration Statement on Form S-8, File No. 333-263428, filed with the SEC on March 10, 2022 by the Registrant, relating to the 2021 Stock Plan and the ESPP, and (iii) the Registration Statement on Form S-8, File No. 333-270387, filed with the SEC on March 9, 2023 by the Registrant relating to the 2021 Stock Plan and the ESPP, except for Item 8, Exhibits, with respect to which the Exhibit Index immediately preceding the exhibits attached hereto is incorporated herein by reference.
Item 8. Exhibits.
The following exhibits are incorporated herein by reference:
Exhibit Number |
|
Description |
|
|
|
4.1 |
|
|
|
|
|
4.2 |
|
|
|
|
|
5.1* |
|
|
|
|
|
23.1* |
|
|
|
|
|
23.2* |
|
Consent of KPMG LLP, Independent Registered Public Accounting Firm. |
|
|
|
24.1* |
|
Power of Attorney (included on the signature pages of this registration statement). |
|
|
|
99.1 |
|
|
|
|
|
99.2 |
|
|
|
|
|
107* |
|
* |
Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 14th day of March, 2024.
|
|
Cullinan Oncology, Inc. |
|
|
|
|
|
Date: March 14, 2024 |
|
By: |
/s/ Nadim Ahmed |
|
|
|
Name: Nadim Ahmed |
|
|
|
Title: President and Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Cullinan Oncology, Inc., hereby severally constitute and appoint Nadim Ahmed and Jeffrey Trigilio, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Cullinan Oncology, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/ Nadim Ahmed |
|
President, Chief Executive Officer and Director |
|
March 14, 2024 |
Nadim Ahmed |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Jeffrey Trigilio |
|
Chief Financial Officer |
|
March 14, 2024 |
Jeffrey Trigilio |
|
(Principal Financial and Accounting Officer) |
|
|
|
|
|
|
|
/s/ Thomas Ebeling |
|
|
|
March 14, 2024 |
Thomas Ebeling |
|
Director |
|
|
|
|
|
|
|
/s/ Anne-Marie Martin |
|
|
|
March 14, 2024 |
Anne-Marie Martin |
|
Director |
|
|
|
|
|
|
|
/s/ Anthony Rosenberg |
|
|
|
March 14, 2024 |
Anthony Rosenberg |
|
Director |
|
|
|
|
|
|
|
/s/ David P. Ryan, M.D. |
|
|
|
March 14, 2024 |
David P. Ryan, M.D. |
|
Director |
|
|
|
|
|
|
|
/s/ Stephen Webster |
|
|
|
March 14, 2024 |
Stephen Webster |
|
Director |
|
|
Exhibit 5.1
|
|
|
|
|
ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM |
March 14, 2024
Cullinan Oncology, Inc.
One Main Street, Suite 1350
Cambridge, MA 02142
Ladies and Gentlemen:
This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the “Registration Statement”), filed by Cullinan Oncology, Inc., a Delaware corporation (the “Company”), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), for the registration of 2,574,005 additional shares of Common Stock, $0.0001 par value per share, of the Company (the “Shares”). Of this amount, 429,001 of the Shares are issuable under the Company’s 2021 Employee Stock Purchase Plan (the “ESPP”), and 2,145,004 of the Shares are issuable under the Company’s 2021 Stock Option and Incentive Plan (together with the ESPP, the “Plans”).
We are familiar with the actions taken by the Company in connection with the adoption of the Plans. We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.
The opinions expressed below are limited to the Delaware General Corporation Law.
Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the Plans, the Shares will be validly issued, fully paid and nonassessable.
We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.
Very truly yours,
/s/ Ropes & Gray LLP
Ropes & Gray LLP
Exhibit 23.2
|
|
|
|
|
KPMG LLP Two Financial Center 60 South Street Boston, MA 02111 |
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated March 14, 2024, with respect to the consolidated financial statements of Cullinan Oncology, Inc., incorporated herein by reference.
|
/s/ KPMG LLP |
Boston, Massachusetts |
March 14, 2024 |
Exhibit 107.1
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Cullinan Oncology, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type |
Security Class Title |
Fee Calculation Rule |
Amount Registered (1) |
Proposed Maximum |
Maximum
|
Fee Rate |
Amount of Registration |
Equity |
Common stock, $0.0001 par value per share |
Rules 457(c) and 457(h) |
429,001 (2) |
$14.07 (3) |
$6,036,044.07 |
0.00014760 |
$890.92 |
Equity |
Common stock, $0.0001 par value per share |
Rules 457(c) and 457(h) |
2,145,004 (4) |
$16.55 (5) |
$35,499,816.20 |
0.00014760 |
$5,239.77 |
Total Offering Amounts |
|
$41,535,860.27 |
|
$6,130.69 |
|||
Total Fee Offsets (6) |
|
|
|
- |
|||
Net Fee Due |
|
|
|
$6,130.69 |
|||
|
|
|
|
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement on Form S-8 (“Registration Statement”) shall also cover any additional shares of the common stock of Cullinan Oncology, Inc. (the “Registrant”) that become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant’s receipt of consideration that results in an increase in the number of the outstanding shares of the Registrant’s common stock. |
(2) |
Represents additional shares of the Registrant’s common stock automatically reserved and available for issuance under the Registrant’s 2021 Employee Stock Purchase Plan (the “2021 ESPP”) resulting from the annual “evergreen” increase in the number of authorized shares reserved and available for issuance under the 2021 ESPP on January 1, 2024. The annual increase was equal to one percent (1%) of the number of shares of common stock issued and outstanding on December 31, 2023. |
(3) |
Estimated in accordance with Rules 457(c) and (h) of the Securities Act, solely for the purpose of calculating the registration fee. The proposed maximum offering price per share is equal to 85% of $16.55, which was computed by averaging the $17.05 (high) and $16.04 (low) prices of a share of the Registrant’s common stock as reported on The Nasdaq Global Select Market on March 11, 2024. Under the 2021 ESPP, the purchase price of a share of common stock is equal to 85% of the fair market value of the Registrant’s common stock on the offering date or the exercise date, whichever is less. |
(4) |
Represents additional shares of the Registrant’s common stock automatically reserved and available for issuance under the Registrant’s 2021 Stock Option and Incentive Plan (the “2021 Plan”) resulting from the annual “evergreen” increase in the number of authorized shares reserved and available for issuance under the 2021 Plan on January 1, 2024. The annual increase was equal to five (5%) percent of the number of shares of stock issued and outstanding on December 31, 2023. |
(5) |
Estimated in accordance with Rules 457(c) and (h) of the Securities Act, solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $16.55 was computed by averaging the $17.05 (high) and $16.04 (low) prices of a share of the Registrant’s common stock as reported on The Nasdaq Global Select Market on March 11, 2024. |
(6) |
The Registrant does not have any fee off-sets. |